title: Therapeutic Toll-like receptor agonists directly influence mouse and human T cell lymphoma cell viability and cytokine secretion.
authors.forename: Angela
authors.initials: A
authors.lastname: Landrigan
authors.forename: Gloria
authors.initials: G
authors.lastname: Yiu
authors.forename: Kanika
authors.initials: K
authors.lastname: Agarwal
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Utz
mesh_terms: D000634:Aminoquinolines / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D018946:Chemokine CCL5 / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D000077271:Imiquimod; D016753:Interleukin-10 / Q000378:metabolism; D016399:Lymphoma, T-Cell / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D051379:Mice; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology*; D013997:Time Factors; D051193:Toll-Like Receptors / Q000819:agonists*
chemical_list: D000634:Aminoquinolines; D000970:Antineoplastic Agents; D018946:Chemokine CCL5; D016207:Cytokines; D009838:Oligodeoxyribonucleotides; C483020:ProMune; D051193:Toll-Like Receptors; D016753:Interleukin-10; D000077271:Imiquimod